

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 65

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 65

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 65

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

amuvatinibum

amuvatinib

N-[(1,3-benzodioxol-5-yl)methyl]-4-([1]benzofuro[3,2-*d*]pyrimidin-4-yl)piperazine-1-carbothioamide


amuvatinib

N-[(1,3-benzodioxol-5-yl)méthyl]-4-([1]benzofuro[3,2-*d*]pyrimidin-4-yl)pipérazine-1-carbothioamide

amuvatinib

N-[(1,3-benzodioxol-5-il)metil]-4-([1]benzofuro[3,2-*d*]pirimidin-4-il)piperazina-1-carbotioamida

C₂₃H₂₁N₅O₃S



anagliptinum

anagliptin

N-[2-({2-[(2*S*)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide


anagliptine

N-[2-({2-[(2*S*)-2-cyanopyrrolidin-1-yl]-2-oxoéthyl}amino)-2-méthylpropyl]-2-méthylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide

anagliptina

N-[2-({2-[(2*S*)-2-cianopirrolidin-1-il]-2-oxoetil}amino)-2-metilpropil]-2-metilpirazolo[1,5-*a*]pirimidina-6-carboxamida

C₁₉H₂₅N₇O₂



atecegatranum


atecegatran

(2*S*)-*N*-[(4-carbamimidoylphenyl)methyl]-1-[(2*R*)-2-[3-chloro-5-(difluoromethoxy)phenyl]-2-hydroxyacetyl]azetidine-2-carboxamide

atécégatran

(2*S*)-*N*-[(4-carbamimidoylphényl)méthyl]-1-[(2*R*)-2-[3-chloro-5-(difluorométhoxy)phényl]-2-hydroxyacétyl]azétidine-2-carboxamide

atecegatrán

(2*S*)-*N*-[(4-carbamimidoilfenil)metil]-1-[(2*R*)-2-[3-cloro-5-(difluorometoxi)fenil]-2-hidroxiacetil]azetidina-2-carboxamida $C_{21}H_{21}ClF_2N_4O_4$ **avibactamum**


avibactam

(1*R*,2*S*,5*R*)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

avibactam

(1*R*,2*S*,5*R*)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide

avibactam

(1*R*,2*S*,5*R*)-7-oxo-6-sulfooxi-1,6-diazabicyclo[3.2.1]octano-2-carboxamida $C_7H_{11}N_3O_6S$ **bavisantum**

bavisant


(4-cyclopropylpiperazin-1-yl){4-[(morpholin-4-yl)methyl]phenyl}methanone

bavisant

(4-cyclopropylpipérazin-1-yl){4-[(morpholin-4-yl)méthyl]phényl}méthanone

bavisant

(4-ciclopropilpiperazin-1-il){4-[(morfolin-4-il)metil]fenil}metanona

 $C_{19}H_{27}N_3O_2$ 

bedaquilinum


bedaquiline

(1*R*,2*S*)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol

bédaquiline

(1*R*,2*S*)-1-(6-bromo-2-méthoxyquinoléin-3-yl)-4-(diméthylamino)-2-(naphthalén-1-yl)-1-phénylbutan-2-ol

bedaquilina

(1*R*,2*S*)-1-(6-bromo-2-metoxiquinolein-3-il)-4-(dimetilamino)-2-(naftalen-1-il)-1-fenilbutan-2-olC₃₂H₃₁BrN₂O₂**brentuximabum vedotinum #**

brentuximab vedotin

immunoglobulin G1-kappa auristatin E conjugate, anti-[*Homo sapiens* TNFRSF8 (tumor necrosis factor receptor superfamily member 8, KI-1, CD30)], chimeric monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-446) [*Mus musculus* VH (IGHV1-84*02 -(IGHD)-IGHJ3*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfide (if not conjugated) with kappa light chain (1'-218') [*Mus musculus* V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (226-226'')-disulfide dimer; conjugated, on an average of 3 to 5 cysteinyl, to monomethylauristatin E (MMAE), via a maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC) linker

For the *vedotin* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

brentuximab védotine

immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[*Homo sapiens* TNFRSF8 (membre 8 de la superfamille des récepteurs du facteur de nécrose tumorale, KI-1, CD30)], anticorps monoclonal chimérique conjugué à l'auristatine E; chaîne lourde gamma1 (1-446) [*Mus musculus* VH (IGHV1-84*02 - (IGHD)-IGHJ3*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfure (si non conjugué) avec la chaîne légère kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (226-226'')-disulfure; conjugué, sur 3 à 5 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker maléimidécaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC)

Pour la partie *védotine*, veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

brentuximab vedotina

inmunoglobulina G1-kappa conjugada con auristatina E, anti-[*Homo sapiens* TNFRSF8 (miembro 8 de la superfamilia de los receptores del factor de necrosis tumoral, KI-1, CD30)], anticuerpo monoclonal quimérico conjugado con auristatina E; cadena pesada gamma1 (1-446) [*Mus musculus* VH (IGHV1-84*02 - (IGHD)-IGHJ3*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01 CH3 K130>del (118-446)], (220-218')-disulfuro (si no está conjugado) con la cadena ligera kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (226-226'')-disulfuro; conjugado, en 3 a 5 residuos cisteinil en término medio, con monometilauristatina E (MMAE), mediante un conector maleimidecaproil-valil-citrulinil-p-aminobenzilcarbamato (mc-val-cit-PABC)
Por la parte *vedotina*, por favor, vaya al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Heavy chain / Chaîne lourde / Cadena pesada

QIQQQSGPE	VVKPGASVKI	SCKASGYTFT	DYYITWVKQK	PGQGLEWIGW	50
IYPGSGNTKY	NEKFKGKATL	TVDTSSSTAF	MQLSSTLSED	TAVYFCANYG	100
NYWFAYWQG	TQVTVSAAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVTVVPS	SSLGTQTYIC	200
NVNHKPSNTK	VKKKVEPKSC	DKTHTCPPCP	APPELLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPSSRDELTK	NQVSLTCLVK	GFYPSTDAVE	WESNGQPENN	YKTTTPPVLD	400
DGSFFLYSKL	TVDKSRWQQG	NVFCSCVMHE	ALHNHYTQKS	LSLSPG	446

Light chain / Chaîne légère / Cadena ligera

DIVLTQSPAS	LAVSLGQRAT	ISCKASQSV	FDGDSYMNWY	QOKFGPPPKV	50
LIYAASNLES	GIPARFSGSG	SGTDFTLNIH	PVEEEDAATY	YCQSNEDPW	100
TFGGGTKLEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCCL	NNFYPREAKV	150
QWKVDNALQS	GNSQESVTEQ	DSKDSTYSL	STLTLSKADY	EKKHKVACEV	200
THQGLSSPVT	KSFNRGEC				218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	144-200	261-321	367-425
	22"-96"	144"-200"	261"-321"	367"-425"
Intra-L	23'-92'	138'-198'		
	23'''-92'''	138'''-198'''		

Inter-H-L * 220-218" 220"-218"

Inter-H-H * 226-226" 229-229"

*Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 5 drug linkers each via a thioether bond.

* Deux ou trois des ponts disulfure ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 5 linker-principe actif chacun via une liaison thioéther.

* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéter, a una media de 3 a 5 conectores de principio activo

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297"

cenicriviroc

cenicriviroc


8-{4-[2-(butoxy)ethoxy]phenyl}-1-(2-methylpropyl)-N-(4-[(1-propyl-1*H*-imidazol-5-yl)methyl]sulfinyl)phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide

cénicriviroc

8-{4-[2-(butoxy)éthoxy]phényl}-1-(2-méthylpropyl)-N-(4-[(1-propyl-1*H*-imidazol-5-yl)méthyl]sulfinyl)phényl)-1,2,3,4-tétrahydro-1-benzazocine-5-carboxamide

cenicriviroc

8-{4-[2-(butoxi)etoxi]fenil}-1-(2-metilpropil)-N-(4-[(1-propil-1*H*-imidazol-5-il)metil]sulfinil)fenil)-1,2,3,4-tetrahidro-1-benzazocina-5-carboxamida

$C_{41}H_{52}N_4O_4S$ **cobicistatum**

cobicistat


(1,3-thiazol-5-yl)methyl (5*S*,8*R*,11*R*)-8,11-dibenzyl-2-methyl-5-[2-(morpholin-4-yl)ethyl]-1-[2-(propan-2-yl)-1,3-thiazol-4-yl]-3,6-dioxo-2,4,7,12-tetraazatridecan-13-oate

cobicistat

(5*S*,8*R*,11*R*)-8,11-dibenzyl-2-méthyl-5-[2-(morpholin-4-yl)éthyl]-1-[2-(propan-2-yl)-1,3-thiazol-4-yl]-3,6-dioxo-2,4,7,12-tétrazatridécan-13-oate de (1,3-thiazol-5-yl)méthyle

cobicistat

(5*S*,8*R*,11*R*)-8,11-dibencil-2-metil-5-[2-(morfolin-4-il)etil]-1-[2-(propan-2-il)-1,3-tiazol-4-il]-3,6-dioxo-2,4,7,12-tetraazatridecan-13-oato de (1,3-tiazol-5-il)metilo

 $C_{40}H_{53}N_7O_5S_2$ **crizotinibum**

crizotinib


3-[(1*R*)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1*H*-pyrazol-4-yl]pyridin-2-amine

crizotinib

3-[(1*R*)-1-(2,6-dichloro-3-fluorophényl)éthoxy]-5-[1-(pipéridin-4-yl)-1*H*-pyrazol-4-yl]pyridin-2-amine

crizotinib

3-[(1*R*)-1-(2,6-dicloro-3-fluorofenil)etoxi]-5-[1-(piperidin-4-il)-1*H*-pirazol-4-il]piridin-2-amina

 $C_{21}H_{22}Cl_2FN_5O$ 

dacomitinibum


dacomitinib

(2*E*)-*N*-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide

dacomitinib

(2*E*)-*N*-{4-[(3-chloro-4-fluorophényl)amino]-7-méthoxyquinazolin-6-yl}-4-(pipéridin-1-yl)but-2-énamide

dacomitinib

(2*E*)-*N*-{4-[(3-cloro-4-fluorofenil)amino]-7-metoxiquinazolin-6-il}-4-(piperidin-1-il)but-2-enamidaC₂₄H₂₅ClFN₅O₂**dexpramipexolum**


dexpramipexole

(6*R*)-*N*⁶-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

dexpramipexole

(6*R*)-*N*⁶-propyl-4,5,6,7-tétrahydro-1,3-benzothiazole-2,6-diamine

dexpramipexol

(6*R*)-*N*⁶-propil-4,5,6,7-tetrahydro-1,3-benzotiazol-2,6-diaminaC₁₀H₁₇N₃S**drozitumabum #**

drozitumab

immunoglobulin G1-lambda, anti-[*Homo sapiens* TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, DR5, death receptor 5, TRAIL-R2, TNF-related apoptosis-inducing ligand receptor 2, TR-2, CD262)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfide with lambda light chain (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-19*01 (96.80%) -IGLJ3*01 [6.3.11] (1'-107') -IGLC3*03 (108'-213'))]; (230-230":233-233")-bisdisulfide dimer

drozitumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* TNFRSF10B (membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale, DR5, death receptor 5, TRAIL-R2, récepteur 2 du ligand inducteur d'une apoptose liée au TNF, TR-2, CD262)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfure avec la chaîne légère lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-19*01 (96.80%) -IGLJ3*01 [6.3.11] (1'-107') -IGLC3*03 (108'-213'))]; dimère (230-230":233-233")-bisdisulfure

drozitumab

inmunoglobulina G1-lambda, anti-[*Homo sapiens* TNFRSF10B (miembro 10B de la superfamilia de receptores del factor de necrosis tumoral, DR5, receptor de muerte 5, TRAIL-R2, receptor 2 del ligando inductor de la apoptosis de la familiaTNF, TR-2, CD262)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-20*01 (91.80%) -(IGHD)-IGHJ2*01 R120>K, L123>T) [8.8.14] (1-121) -IGHG1*03 CH1 R120>K (122-451)], (224-212')-disulfuro con la cadena ligera lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-19*01 (96.80%) -IGLJ3*01) [6.3.11] (1'-107') -IGLC3*03 (108'-213')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVQSGGG	VERPGGSLRL	SCAASGFTFD	DYAMSWVRQA	PGKGLEWVSG	50
INWQGGSTGY	ADSVKGRVTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCAKIL	100
GAGRGWYFDY	WGKGTIVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAALGCLV	150
KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ	200
TYICNVNHKP	SNTKVDKKVE	PKSCDKTHTC	PCCPAPELLG	GPSVFLFPPK	250
PKDTLMISRT	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	300
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	350
QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNNYKTTTP	400
VLDSDGSFFL	YSKLTVDKSR	WQQGNVFSCS	VMHEALHNNH	TQKSLSLSPG	450
K					451

Light chain / Chaîne légère / Cadena ligera

SELTQDPAVS	VALGQTVRIT	CSGDSLRSYY	ASWYQQKPGQ	APVLVIYGAN	50
NRPSGIPDRF	SGSSSGNTAS	LTITGAQAE	EADYYCNSAD	SSGNHVVFEG	100
GTKLTVLGQP	KAAPSVTLFP	PSSEELQANK	ATLVCLISDF	YPGAVTVAWK	150
ADSSPVKAGV	ETTPPSKQSN	NKYAASSYLS	LTPEQWKSHK	SYSCQVTHEG	200
STVEKTVAPT	ECS				213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L	21'-86'	135'-194'		
	21"-86"	135"-194"		
Inter-H-L	224-212"	224"-212"		
Inter-H-H	230-230"	233-233"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

301, 301"

dulaglutidum #
dulaglutide

glucagon-like peptide-1-immunoglobulin G4 fusion protein, [2-glycyl, 16-L-glutamyl, 30-glycyl][human glucagon-like peptide 1-(7-37)-peptide] {(8-A>G, 22-G>E, 36-R>G)-GLP-1(7-37)} fusion protein with tris(tetraglycyl-L-seryl)-L-alanine (linker) fusion protein with des-276-lysine-[57-L-proline, 63-L-alanine, 64-L-alanine]human immunoglobulin G4 Fc region {(10-S>P)-H-(4-F>A, 5-L>A)-CH2-(107-K>-)-CH3 of IGHG4*01}, dimer (55-55':58-58')-bisdisulfide

dulaglutide

protéine de fusion entre le peptide 1 semblable au glucagon et l'immunoglobuline G4,
[2-glycyl, 16-L-glutamyl, 30-glycyl][peptide 1 semblable au glucagon humain-(7-37)-peptide] {(8-A>G, 22-G>E, 36-R>G)GLP-1(7-37)} protéine de fusion avec le tris(tétraglycyl-L-séryl)-L-alanine (lien) protéine de fusion avec la dès-276-lysine-[57-L-proline, 63-L-alanine, 64-L-alanine]région Fc de l'immunoglobuline G4 humaine {(10-S>P)H-(4-F>A, 5-L>A)CH2-(107-K>-)CH3 du IGHG4*01}, (55-55':58-58')-bisdisulfure du dimère

dulaglutida

proteína de fusión entre el péptido similar al glucagón 1 y la inmunoglobulina G4, [2-glicil,16-L-glutamil,30-glicil][péptido similar al glucagón humano 1-(7-37)-péptido] {(8-A>G,22-G>E,36-R>G)GLP-1(7-37)} proteína de fusión con el tris(tetraglicil-L-seril)-L-alanina (vínculo) proteína de fusión con la des-276-lisina-[57-L-prolina, 63-L-alanina,64-L-alanina]región Fc de la inmunoglobulina G4 humana {(10-S>P)H-(4-F>A,5-L>A)CH2-(107-K>-)CH3 delIGHG4*01}, (55-55':58-58')-bisdisulfuro del dímero

$$C_{2646}H_{4044}N_{704}O_{836}S_{18}$$

Monomer / Monomère / Monomero

HGEGTFTSDV	SSYLEEQAAK	EFIWLKVGK	GGGGSGGGG	SGGGGSAESK	50
YGPFCPCPA	PEAAGGPSVF	LFPPKPKDTL	MISRTPEVTC	VVVDVSQEDP	100
EVQFNWYVDG	VEVHNAKTKP	REEQFNSTYR	VVSVLTVLHQ	DWLNKEYKC	150
KVSNKGLPSS	IEKTISKAKG	QPREPQVYTL	PFSQEEMTKN	QVSLTCLVKG	200
FYPSDIAVEW	ESNGQPENNY	KTTFPVLDSD	GSFFLYSRLT	VDKSRWQEGN	250
VFSCSVMEHA	LHNHYTQKSL	SLSLG			275

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
55-55' 58-58' 90-150 90'-150' 196-254 196'-254'

eliglustatum

eliglustat


N-{[(1*R*,2*R*)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanamide

éliglustat

N-{[(1*R*,2*R*)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl]octanamide

eliglustat

N-{[(1*R*,2*R*)-1-(2,3-dihidro-1,4-benzodioxin-6-il)-1-hidroxi-3-(pirrolidin-1-il)propan-2-il]octanamida

$$C_{23}H_{36}N_2O_4$$
**elpamotidum**

elpamotide

L-arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-α-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine human soluble (Vascular Endothelial Growth Factor Receptor) VEGFR2-(169-177)-peptide

elpamotide

L-arginyl-L-phénylalanyl-L-valyl-L-prolyl-L-α-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine (Récepteur du Facteur de Croissance de l'Endothélium Vasculaire) RFCEV2 soluble humain-(169-177)-peptide

elpamotida

L-arginil-L-fenilalanil-L-valil-L-prolil-L-α-aspartilglicil-L-asparaginil-L-arginil-L-isoleucina (receptor del factor de crecimiento endotelial vascular) RFCEV2 soluble humano-(169-177)-péptido

$$C_{47}H_{76}N_{16}O_{13}$$

H-Arg-Phe-Val-Pro-Asp-Gly-Asn-Arg-Ile-OH
9

ensituximabum #

ensituximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC5AC (mucin 5AC, mucin 5 subtypes A and C tracheobronchial/gastric)], chimeric monoclonal antibody;

gamma1 heavy chain (1-443) [*Mus musculus* VH (IGHV2-3*01 - (IGHD)-IGHJ4*01) [8.7.7] (1-113) -*Homo sapiens* IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-70*01 - IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (222-222'':225-225'')-bisdisulfide dimer

ensituximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC5AC (mucine 5AC, mucine 5 de sous-types A et C trachéo-bronchique/gastrique)], anticorps monoclonal chimérique;

chaîne lourde gamma1 (1-443) [*Mus musculus* VH (IGHV2-3*01 - (IGHD)-IGHJ4*01) [8.7.7] (1-113) -*Homo sapiens* IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-70*01 - IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (222-222'':225-225'')-bisdisulfure

ensituximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MUC5AC (mucina 5AC, mucina 5 de subtipos A y C traqueo-bronquial/gástrico)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 (1-443) [*Mus musculus* VH (IGHV2-3*01 - (IGHD)-IGHJ4*01) [8.7.7] (1-113) -*Homo sapiens* IGHG1*01 CH1 L85.3>P, CH3 T81>M (114-443)], (216-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-70*01 - IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (222-222'':225-225'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLKESGPD	LVAPSQSLSI	TCTVSGFSL	KFGVNWVRQP	PGKGLEWLG	50
IWGDGSTSYN	SGLISRLSIS	KENSKSQVFL	KLNSLQADDT	ATYYCVKPGG	100
DYWGHTSVT	VSSASTKGPS	VFPLAPSSKS	TSGGTAALGC	LVKDYFPEPV	150
TVSWNSGALT	SGVHTFPAVL	QSSGPYSLS	VVTVPSSSLG	TQTYICNVNH	200
KPSNTKVDKK	VEPKSCDKTH	TCPPCPAPEL	LGGPSVFLFP	PKPKDTLMIS	250
RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV	HNAKTKPREE	QYNSTYRVVS	300
VLTVLHQDWL	NGKEYKCKVS	NKALPAPIEK	TISKAKGQPR	EPQVYTLPPS	350
RDELTKNQVS	LTCLVKGFYP	SDIAVEWESN	GQPENNYKTM	PPVLDSDGSF	400
FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN	HYTQKSLSL	PGK	443

Light chain / Chaîne légère / Cadena ligera

QVVLTSQSPVI	MSASPGEKVT	MTCSSASSIS	YMYWYQKPG	TSPKRWIYDT	50
SKLASGVPAR	FSGSGSGTSY	SLTISNMEAG	DAATYYCHQR	DSYPWTFGGG	100
TNLEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150
NALQSGNSQE	SVTEQDSKDS	TYSLSTLTTL	SKADYEKKHV	YACEVTHQGL	200
SSPVTKSFNR	GEC				213


Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95	140-196	257-317	363-421
	22"-95"	140"-196"	257"-317"	363"-421"
Intra-L	23'-87'	133'-193'		
	23'''-87'''	133'''-193'''		
Inter-H-L	216-213'	216"-213'"		
Inter-H-H	222-222"	225-225"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

293, 293"

tout-P-ambo-5'-{P-[4-{(2-[2-(2-hydroxyéthoxy)éthoxyléthoxy}carbonyl)pipérazin-1-yl]-N,N-diméthylphosphonamide)-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocytidylyl-(2'a→5')-P,3'-didésoxy-P-diméthylamino-2',3'-imino-2',3'-sécothymidyllyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocytidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoguanilyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoguanilyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoguanilyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocytidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoguanilyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocytidylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoguanilyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoadénylyl-(2'a→5')-P,2',3'-tridésoxy-P-diméthylamino-2',3'-imino-2',3'-séocoguanosine

[illegible]

B(1-30):
C-T-C-C-A-A-C-A-T-C-A-A-G-G-A-A-G-A-T-G-G-C-A-T-T-T-C-T-A-G

fasitibanti chloridum


fasitibant chloride

(4*S*)-4-amino-5-{4-[4-(2,4-dichloro-3-[(2,4-dimethylquinolin-8-yl)oxy]methyl)benzenesulfonamido]oxane-4-carbonyl]piperazin-1-yl}-*N,N,N*-trimethyl-5-oxopentan-1-aminium chloride

chlorure de fasitibant

chlorure de (4*S*)-4-amino-5-{4-[4-(2,4-dichloro-3-[(2,4-diméthylquinoléin-8-yl)oxy]méthyl)benzènesulfonamido]oxane-4-carbonyl]pipérazin-1-yl}-*N,N,N*-triméthyl-5-oxopentan-1-aminium

cloruro de fasitibant

cloruro de (4*S*)-4-amino-5-{4-[4-(2,4-dicloro-3-[(2,4-dimetilquinolein-8-il)oxi]metil]bencenosulfonamido]oxano-4-carbonil]piperazin-1-il}-*N,N,N*-trimetil-5-oxopentan-1-aminioC₃₆H₄₉Cl₃N₆O₆S**fedovapagonum**


fedovapagon



(2*S*)-*N*²,*N*²-dimethyl-*N*¹-{[2-methyl-4-(2,3,4,5-tetrahydro-1*H*-1-benzazepine-1-carbonyl)phenyl]methyl}pyrrolidine-1,2-dicarboxamide

fédovapagon

(2*S*)-*N*²,*N*²-diméthyl-*N*¹-{[2-méthyl-4-(2,3,4,5-tétrahydro-1*H*-1-benzazépine-1-carbonyl)phényl]méthyl}pyrrolidine-1,2-dicarboxamide

fedovapagón

(2*S*)-*N*²,*N*²-dimetil-*N*¹-{[2-metil-4-(2,3,4,5-tetrahydro-1*H*-1-benzazepina-1-carbonil)fenil]metil}pirrolidina-1,2-dicarboxamidaC₂₇H₃₄N₄O₃**florbetapirum (¹⁸F)**florbetapir (¹⁸F)4-[(1*E*)-2-(6-{2-[2-(2-[¹⁸F]fluoroethoxy)ethoxy]ethoxy}pyridine-3-yl)ethen-1-yl]-*N*-methylanilineflorbétapir (¹⁸F)4-[(1*E*)-2-(6-{2-[2-(2-[¹⁸F]fluoroéthoxy)éthoxy]éthoxy}pyridin-3-yl)éthén-1-yl]-*N*-méthylanilineflorbetapir (¹⁸F)4-[(1*E*)-2-(6-{2-[2-(2-[¹⁸F]fluoroetoxi)etoxi]etoxi}piridin-3-il)eten-1-il]-*N*-metilanilina



fluciclatidum (¹⁸F)
fluciclatide (¹⁸F)



*N*⁶-[(2*E*)-29-(4-[¹⁸F]fluorophenyl)-5,25-dioxo-3,9,12,15,18,21,27-hepta-6,24,28-triazanonacos-28-enoyl]-*N*²-(sulfanylacetyl)-L-lysyl-L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-cysteinyl-L-phenylalanyl-*N*-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecyl)-L-cysteinamide cyclic (2→6)-disulfide cyclic (1→8)-thioether

fluciclatide (¹⁸F)

(2→6)-disulfure cyclique et (1→8)-thioéther cyclique du *N*⁶-[(2*E*)-29-(4-[¹⁸F]fluorophényl)-5,25-dioxo-3,9,12,15,18,21,27-hepta-6,24,28-triazanonacos-28-énoyl]-*N*²-(2-sulfanylacétyl)-L-lysyl-L-cystéinyl-L-arginylglycyl-L-α-aspartyl-L-cystéinyl-L-phénylalanyl-1-*N*-(17-amino-13,17-dioxo-3,6,9,15-tétraoxa-12-azaheptadécyl)-L-cystéinamide

fluciclatida (¹⁸F)

(2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del *N*⁶-[(2*E*)-29-(4-[¹⁸F]fluorofenil)-5,25-dioxo-3,9,12,15,18,21,27-hepta-6,24,28-triazanonacos-28-enoil]-*N*²-(2-sulfanilacetil)-L-lisil-L-cisteinil-L-arginilglicil-L-α-aspartil-L-cisteinil-L-fenilalanil-1-*N*-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecil)-L-cisteinamida



fluciclovium (¹⁸F)
fluciclovine (¹⁸F)


(1*r*,3*r*)-1-amino-3-[¹⁸F]fluorocyclobutane-1-carboxylic acid


fluciclovine (¹⁸F)

acide *trans*-1-amino-3-[¹⁸F]fluorocyclobutane-1-carboxylique

fluciclovina (¹⁸F)

ácido (1*r*,3*r*)-1-amino-3-[¹⁸F]fluorociclobutano-1-carboxílico



flurpiridazum (¹⁸F)flurpiridaz (¹⁸F)2-*tert*-butyl-4-chloro-5-({4-[(2-[¹⁸F]fluoroethoxy)methyl]phenyl}methoxy)pyridazin-3(2*H*)-oneflurpiridaz (¹⁸F)2-*tert*-butyl-4-chloro-5-({4-[(2-[¹⁸F]fluoroéthoxy)méthyl]phényl}méthoxy)pyridazin-3(2*H*)-oneflurpiridaz (¹⁸F)2-*terc*-butil-4-cloro-5-({4-[(2-[¹⁸F]fluoroetoxi)metil]fenil}metoxi)piridazin-3(2*H*)-onaC₁₈H₂₂Cl¹⁸FN₂O₃**foralumabum #**

foralumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (227-227'':230-230'')-bisdisulfide dimer

foralumab

immunoglobuline G1 -kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma1 (1-448) [*Homo sapiens* (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (227-227'':230-230'')-bisdisulfure

foralumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon)], anticuerpo monoclonal de *Homo sapiens*;
 cadena pesada gamma1 (1-448) [*Homo sapiens* (IGHV3-33*01 (95.90%) -(IGHD)-IGHJ2*01) [8.8.11] (1-118) -IGHG1*03 CH2 L1.3(235)>A, L1.2(236)>E (119-448)], (221-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada			
QVQLVESGGG	VVQPGRSRLRL	SCAASGFKFS	GYGMHWVRQA
IWYDGSKKYY	VDSVKGRFTI	SRDNSKNTLY	LQMNSLRAED
GYWHFDLWGR	GTLVTVSSAS	TKGPSVFPLA	PSSKSTSGGT
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVTVP
CNVNHKPSNT	KVDKRVEPKS	CDKHTCPCPC	PAPEAEGGPS
TLMISRTPEV	TCVVVDVSHE	DPEVKFNWYV	DGVEVHNAKT
YRVVSVLTVL	HQDWLNGKEY	KCKVSNKALP	APIEKTISKA
TLPPSREEMT	KNQVSLTCLV	KGFYPSDIAV	EWESNGQFEN
SDGSFFLYSK	LTVDKSRWQQ	GNVFSCSVMH	EALHNHYTQK
Light chain / Chaîne légère / Cadena ligera			
EIVLTQSPAT	LSLSPGERAT	LSCRASQSVS	SYLAWYQQKP
ASNRATGIPA	RFGSGSGTD	FTLTISSELP	EDFAVYYCQQ
GGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNNF
VDNALQSGNS	QESVTEQDSK	DSTYSLSSLT	TLSKADYEKH
GLSSPVTKSF	NRGEC		

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro			
Intra-H	22-96	145-201	262-322
	22"-96"	145"-201"	262"-322"
Intra-L	23'-88'	135'-195'	
	23"-88"	135"-195"	
Inter-H-L	221-215'	221"-215"	
Inter-H-H	227-227"	230-230"	

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"

fosdevirinum
fosdevirine



methyl (R)-(2-carbamoyl-5-chloro-1H-indol-3-yl){3-[(1E)-2-cyanoethen-1-yl]-5-methylphenyl}phosphinate

fosdévirine

(R)-(2-carbamoyl-5-chloro-1H-indol-3-yl){3-[(1E)-2-cyanoéthén-1-yl]-5-méthylphényl}phosphinate de méthyle

fosdevirina

(R)-(2-carbamoiil-5-cloro-1H-indol-3-il){3-[(1E)-2-cianoeten-1-il]-5-metilfenil}fosfinato de metilo



ganitumabum #
ganitumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [*Homo sapiens* V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer

ganitumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline, IGF1-R, IGF-1R, CD221)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-449) [<i>Homo sapiens</i> VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [<i>Homo sapiens</i> V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure
ganitumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> IGF1R (receptor del factor de crecimiento 1 análogo a la insulina, IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-449) [<i>Homo sapiens</i> VH (IGHV4-4*02 (100.00%) -(IGHD)-IGHJ3*02) [9.7.12] (1-119) -IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [<i>Homo sapiens</i> V-KAPPA (IGKV2-28*01 (95.00%) -IGKJ1*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro
	<p>Heavy chain / Chaîne lourde / Cadena pesada</p> <p>QVQLQESGPG LVKPSGTLSTL TCAVSGGSIS SSNWSWVRQ PPGKGLEWIG 50 EIIYHSGSTNY NPSLKSRTVI SVDKSKNQFS LKLSSTAAD TAVYYCARWT 100 GRDADFIDWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFPVQLQSSG LYSLSVVTV PSSSLGTQTY 200 ICNVNHNKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPKPK 250 DTLMISRTPV VTCVVDVSH EDPVVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVSVSLTV LKQDNLNGKE YCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400 DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449</p> <p>Light chain / Chaîne légère / Cadena ligera</p> <p>DVVMTQSPPLS LPVTPGEPAS ISCRSSQSLL HSNNGYNLDW YLQKPGQSPQ 50 LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI SRVEAEDGVV YYCMQGTHTW 100 LTFGGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNIFYPREAK 150 VQWVKDNLQ SGNSQESVTE QDSKSTYSL SSTLTLSKAD YEKHKVYACE 200 VTHQGLSSPV TKSFNREGC 219</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>Intra-H 22-96 146-202 263-323 369-427 22"-96" 146"-202" 263"-323" 369"-427"</p> <p>Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199'''</p> <p>Inter-H-L 222-219' 222"-219"</p> <p>Inter-H-H 228-228" 231-231"</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 299, 299"</p>
gataparsenum gataparsen	<i>all-P-ambo</i> -2'-O-(2-methoxyethyl)-5-methyl- <i>P</i> -thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)- <i>P</i> -thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl- <i>P</i> -thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)- <i>P</i> -thioguanylyl-(3'→5')-2'-deoxy-5-methyl- <i>P</i> -thiocytidylyl-(3'→5')- <i>P</i> -thiothymidylyl-(3'→5')-2'-deoxy- <i>P</i> -thioadenylyl-(3'→5')- <i>P</i> -thiothymidylyl-(3'→5')- <i>P</i> -thiothymidylyl-(3'→5')-2'-deoxy-5-methyl- <i>P</i> -thiocytydilyl-(3'→5')- <i>P</i> -thiothymidylyl-(3'→5')-2'-deoxy- <i>P</i> -thioguanylyl-(3'→5')- <i>P</i> -thiothymidylyl-(3'→5')-2'-deoxy- <i>P</i> -thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)- <i>P</i> -thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)- <i>P</i> -thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl- <i>P</i> -thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine

gataparsen

tout-P-ambo-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanilyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanilyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyluridine


gataparsén

todo-P-ambo-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina

C₂₀₄H₂₇₈N₅₉O₁₁₁P₁₇S₁₇

(3'→5')d(P-thio)(rU-rG-rU-rG-C-T-A-T-T-C-T-G-T-G-rA-rA-rU-rU)

Modified nucleosides / Nucléosides modifiés / Nucleosidos modificados:

gemigliptinum
gemigliptin



1-((2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl)-5,5-difluoropiperidin-2-one

gémigliptine

1-((2S)-2-amino-4-[2,4-bis(trifluorométhyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl)-5,5-difluoropipéridin-2-one

gemigliptina

1-((2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-dihidropirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutyl)-5,5-difluoropiperidin-2-ona

**iniparibum**

iniparib



4-iodo-3-nitrobenzamide

iniparib

4-iodo-3-nitrobenzamide

iniparib

4-iodo-3-nitrobenzamida

**insulinum tregopilum**



insulin tregopil



 $N^{6,29B}$ -(4,7,10,13-tetraoxatetradecanoyl)human insulin

insuline tregopil

 $N^{6,29B}$ -(4,7,10,13-tétraoxatétradécanoyl)insuline humaine

insulina tregopilo

 $N^{6,29B}$ -(4,7,10,13-tetraoxatetradecanoyl)insulina humana**ioflubenzamidum (^{131}I)**ioflubenzamide (^{131}I) N -[2-(diethylamino)ethyl]-4-(4-fluorobenzamido)-5- ^{131}I iodo-2-methoxybenzamideioflubenzamide (^{131}I) N -[2-(diéthylamino)éthyl]-4-(4-fluorobenzamido)-5- ^{131}I iodo-2-méthoxybenzamideioflubenzamida (^{131}I) N -[2-(diethylamino)etil]-4-(4-fluorobenzamido)-5- ^{131}I iodo-2-metoxibenzamida

**ioforminolum**

ioforminol


all-ambo-5,5'-[2-hydroxypropane-1,3-diylbis(formylazanediy)]bis[*N,N'*-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide]

ioforminol

tout-ambo-5,5'-[2-hydroxypropane-1,3-diylbis(formylazanediy)]bis[*N,N'*-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzène-1,3-dicarboxamide]

ioforminol

todo-ambo-5,5'-[2-hidroxiopropano-1,3-diilbis(formilazanodiil)]bis[*N,N'*-bis(2,3-dihidroxiopropil)-2,4,6-triiodobenceno-1,3-dicarboxamida]

**ipragliflozinum**

ipragliflozin


(1*S*)-1,5-anhydro-1-*C*-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-*D*-glucitol

ipragliflozine

(1*S*)-1,5-anhydro-1-*C*-{3-[(1-benzothiophén-2-yl)méthyl]-4-fluorophényl}-*D*-glucitol

ipragliflozina

(1*S*)-1,5-anhidro-1-*C*-{3-[(1-benzotiofen-2-il)metil]-4-fluorofenil}-*D*-glucitol
 $\text{C}_{21}\text{H}_{21}\text{FO}_5\text{S}$



itarnafloxinum

itarnafloxin


5-fluoro-*N*-{2-[(2*S*)-1-méthylpyrrolidin-2-yl]éthyl}-3-oxo-6-[(3*RS*)-3-(pyrazin-2-yl)pyrrolidin-1-yl]-3*H*-benzo[*b*]pyrido[3,2,1-*k*]phénoxazine-2-carboxamide

itarnafloxine

5-fluoro-*N*-{2-[(2*S*)-1-méthylpyrrolidin-2-yl]éthyl}-3-oxo-6-[3-(pyrazin-2-yl)pyrrolidin-1-yl]-3*H*-benzo[*b*]pyrido[3,2,1-*k*]phénoxazine-2-carboxamide

itarnafloxina

5-fluoro-*N*-{2-[(2*S*)-1-metilpirrolidin-2-il]etil}-3-oxo-6-[(3*RS*)-3-(pirazin-2-il)pirrolidin-1-il]-3*H*-benzo[*b*]pirido[3,2,1-*k*]fenoxazina-2-carboxamida

C₃₅H₃₃FN₆O₃**itolizumabum #**

itolizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD6 (Tp120, T12)], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

itolizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD6 (Tp120, T12)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

itolizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD6 (Tp120, T12)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens*IGHV3-21*08 (83.70%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens*IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-17*01 (76.80%) -IGKJ2*01 F118>L, Q120>S) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVQLVESGGG LVKPGGSLKL SCAASGFKFS RYAMSWVRQA PGKRLEWVAT 50
ISSGGSYIYY PDSVKGRFTI SRDNVKNLTLY LQMSSLRSED TAMYYCARRD 100
YDLDFDSDWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTSW NSGALTSGVH TFPVQLQSSG LYSLSVTVV PSSSLGTQTY 200
ICNVNHHKPSN TKVDKKVEPK SCDKTHCTCP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS LSASVGDRTV ITCKASRDIT SYLTWYQQKPK GKAPKTLIYY 50
ATSLADGVPS RFSGSGSGQD YSLTISSLES DDTATYYCLQ HGESPTFLGS 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEK 214

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 146-202 263-323 369-427
        22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-88' 134'-194'
        23'"-88'" 134'"-194'"
Inter-H-L 222-214' 222"-214"
Inter-H-H 228-228" 231-231"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

lorvotuzumabum mertansinum #
lorvotuzumab mertansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* NCAM1 (neural cell adhesion molecule 1, CD56, NCAM-1)], humanized monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens*IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (227-227":230-230")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a thiopentanoate linker

For the *mertansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*"**

lorvotuzumab mertansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* NCAM1 (molécule d'adhésion 1 de cellule neurale, CD56, NCAM-1)], anticorps monoclonal humanisé conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (227-227":230-230")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker thiopentanoate

Pour la partie *mertansine*, veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*"**.

lorvotuzumab mertansina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* NCAM1 (molécula de adhesión 1 de célula neural, CD56, NCAM-1)], anticuerpo monoclonal humanizado conjugado con maitansinoide DM1; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens*IGHV3-30*03 (91.80%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens*IGKV2-30*02 (92.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (227-227":230-230")-bisdisulfuro; conjugado, en 3 a 4 residuos lisil por término medio, con maitansinoide DM1 con un conector tiopentanoato
Por la parte *mertansina*, por favor, vaya al documento "INN for pharmaceutical substances: Names for radicals, groups & others".

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG VVQPGKSLRL SCAASGFTFS SFGMHWRQA PGKLEWVAY 50
ISSGSFTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARMR 100
KGYAMDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKHTCTPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVDVDSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSTIAV EWESNGQPEN NYKTTTPPVL 400
SDGSFFLYSK LTVDKSRWQQ GNVFCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera

DVVMTQSPLS LPVTLGQPAS ISCRSSQIII HSDGNTYLEW FQRPQGSPR 50
RLIYKVSNRG SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YICFPQSHVP 100
HTFGQGTKEV IKRTVAAPSV FIFPPSDEQL KSGTASVVC LNNFYFREAK 150
VQWKVDNALQ SGNSQESVTE QDSKSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L 23'-93' 139'-199'
23"'-93'" 139"'-199'"
Inter-H-L 221-219' 221"-219"
Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"maraciclátidum
maraciclátide


N^6 -(5-([3-(hidroxiimino)-2-metilbutan-2-il]amino)-3-(2-([3-(hidroxiimino)-2-metilbutan-2-il]amino)etil)pentil]amino)-5-oxopentanoyl)- N^2 -(2-sulfanilacetil)-L-lisil-L-cisteinil-L-arginilglycil-L- α -aspartil-L-cisteinil-L-fenilalanil-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecil)-L-cisteinamida cíclico (2→6)-disulfuro cíclico (1→8)-tioéter

maraciclátide

(2→6)-disulfuro cíclico et (1→8)-tioéter cíclico du N^6 -(5-([3-(hidroxiimino)-2-metilbutan-2-il]amino)-3-(2-([3-(hidroxiimino)-2-metilbutan-2-il]amino)etil)pentil]amino)-5-oxopentanoyl)- N^2 -(2-sulfanilacétyl)-L-lisyl-L-cystéinil-L-arginilglycil-L- α -aspartil-L-cystéinil-L-phénylalanil-1-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadécyl)-L-cystéinamida

maraciclátida

(2→6)-disulfuro cíclico y (1→8)-tioéter cíclico del N^6 -(5-([3-(hidroxiimino)-2-metilbutan-2-il]amino)-3-(2-([2-(hidroxiimino)-2-metilbutan-2-il]amino)etil)pentil]amino)-5-oxopentanoyl)- N^2 -(2-sulfanilacetil)-L-lisil-L-cisteinil-L- α -aspartil-L-cisteinil-L-fenilalanil-1-N-(17-amino-13,17-dioxo-3,6,9,15-tetraoxa-12-azaheptadecil)-L-cisteinamida



navitoclaxum

navitoclax


4-(4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-*N*-(4-[[[(2*R*)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino]-3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide

navitoclax

4-(4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl]piperazin-1-yl)-*N*-(4-[[[(2*R*)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino]-3-(trifluoromethanesulfonyl)benzenesulfonyl]benzamide

navitoclax

4-(4-[[2-(4-clorofenil)-5,5-dimetilciclohex-1-en-1-il]metil]piperazin-1-il)-*N*-(4-[[[(2*R*)-1-(fenilsulfanil)-4-(morfolin-4-il)-butan-2-il]amino]-3-(trifluorometanosulfonyl)benzenosulfonyl]benzamida

 $C_{47}H_{55}ClF_3N_5O_6S_3$
**nonacogum beta pegolum #**

nonacog beta pegol

pegylated human blood coagulation factor IX;
human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), en average of one sialyl unit of the N-linked carbohydrates are 5-*N*-[*N*-({2,3-bis[ω-methoxypoly(oxyethane-1,2-diyl)]propoxy}carbonyl)glycyl]-5-*N*-deacetyl

nonacog bêta pégol

facteur IX humain de coagulation sanguine, pégylé;
facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophile B) dont quelques unités sialyl, en moyenne une par molécule d'enzyme, de la partie N-glycosyl sont 5-*N*-[*N*-({2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}carbonyl)glycyl]-5-*N*-désacétyl


nonacog beta pegol

factor IX humano de coagulación sanguínea, pegilado;
factor IX humano de coagulación (EC 3.4.21.22, factor Christmas, factor antihemofílico B) algunas de cuyas unidades sialil, una por molécula de enzima, por término medio, de la fracción N-glicosil son 5-*N*-[*N*-({2,3-bis[ω-metoxipoli(oxiétilen)]propoxi}carbonil)glicil]-5-*N*-desacetil

YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTE FWKQYVDGQ 50
 CESNPCLNGG SKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100
 NSADNKVCS CTEGYRLAEN QKSCEPAVVF PCGRVSVSQT SKLTRAFAVF 150
 PDVDYVNSTE AETILDNITQ STQSFNDFTR VVGEDAKPG QFPWQVVLNG 200
 KVDATFCGSI VNEKIWTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRN 250
 IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSVTPICI ADKEYTNIFL 300
 KFGSGYVSGW GRVFHKGSA LVLQYLRVPL VDRATCLRST KFTIYNMFC 350
 AGFHEGGRDS CQGDGSGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 400
 VSRYVNIKE KTKLT 415

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 18-23 51-62 56-71 73-82 88-99 95-109
 111-124 132-289 206-222 336-350 361-389

Modified residues / Résidus modifiés / Residuos modificados



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-157 Asn-167
 $R \rightarrow 3\text{-}\beta\text{-Gal} \rightarrow 3\text{-}\beta\text{-Gl-N} \rightarrow 2\text{-}\alpha\text{-Man} \rightarrow 6\text{-}\beta\text{-Man} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow N$
 $R' \rightarrow 3\text{-}\beta\text{-Gal} \rightarrow 3\text{-}\beta\text{-Gl-N} \rightarrow 2\text{-}\alpha\text{-Man} \rightarrow 3\text{-}\beta\text{-Man} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow 4\text{-}\beta\text{-Gl-N} \rightarrow N$

R = α -Sia, R' = α -Sia or PEG- α -Sia or R' = α -Sia, R = α -Sia or PEG- α -Sia

Gal = D-galactopyranosyl

Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl

Man = D-mannopyranosyl

PEG- = O- $\{\alpha$ -methylpoly(oxyethylene) hydrogen phosphate]

Sia = 5-N-acetyl- α -neuramin-2-yl

Other positions of post-translational modifications:

partial-hydroxylation of Asp64; O-linked glycosylation on positions Ser53 and Ser61,
 partially O-linked glycosylation on positions Thr159 and Thr169

Autres positions de modifications post-traductionnelles:

hydroxylation partielle de Asp64; glycosylation O-liée sur les positions Sér53 et Sér61,
 glycosylation partielle O-liée sur les positions Thr159 et Thr169

Otras posiciones de modificaciones post-traducción

hidroxilación parcial de Asp64; glicosilación O-ligada en las posiciones Ser53 y Ser61,
 glicosilación parcial O-ligada en las posiciones Thr159 y Thr169

obinutuzumabum # obinutuzumab

immunoglobulin G1, anti-[*Homo sapiens* CD20 (membrane-spanning 4-domains subfamily A member 1, MS4A1, B lymphocyte surface antigen B1, Leu-16, Bp35)], humanized monoclonal antibody, GA101;

gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01 (120-448)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ4*01) [11.3.9] (1'-112') - *Homo sapiens* IGKC*01 (113'-219')]; (228-228'':231-231'')-bisdisulfide dimer

immunomodulator

obinutuzumab

immunoglobuline G1, anti-[*Homo sapiens* CD20 (membre 1 de la sous-famille A à 4 domaines transmembranaires, MS4A1, antigène de surface B1 des lymphocytes B, Leu-16, Bp35)], anticorps monoclonal humanisé, GA101;

chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01 (120-448)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ4*01) [11.3.9] (1'-112') - *Homo sapiens* IGKC*01 (113'-219')]; dimère (228-228'':231-231'')-bisdisulfure

immunomodulateur

obinutuzumab

inmunoglobulina G1, anti-[*Homo sapiens* CD20 (miembro 1 de la sub-familia A de 4 dominios transmembranarios, MS4A1, antígeno de superficie B1 de los linfocitos B, Leu-16, Bp35)], anticuerpo monoclonal humanizado, GA101; cadena pesada gamma1 (1-448) [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*01 (120-448)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR, *Homo sapiens* IGKJ4*01) [11.3.9] (1'-112') - *Homo sapiens* IGKC*01 (113'-219')]; dímero (228-228'':231-231'')-bisdisulfuro
inmunomodulador

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR 50
IFPGDGDSTDY NGKFKGRVTI TADKSTSTAY MELSSSLRSED TAVYYCARNV 100
FDGYWLVYWG QGTLVTSSA STKGPSVFPPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPVAVLQSSG LYSLSVTVV PSSSLGTQTY 200
ICNVNHNKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGSP SVFLFPPKPK 250
DTLMISRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIETISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNYTQ KLSLSLSPGK 449

```

Light chain / Chaîne légère / Cadena ligera

```

DIVMTQTPLS LPVTPGEPAS ISCRSSSKSL HSNGITYLYW YLQKPGQSPQ 50'
LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI SRVEADVGV YYCAQNLELP 100'
YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150'
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200'
VTHQGLSSPV TKSFNRGEC 219'

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-96 22'-96" 23'-93" 23"-93" 139'-199' 139"-199" 146-202 146"-202"
219-222 219"-222" 228-228" 231-231" 263-323 263"-323" 369-427 369"-427"

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Ser-53 Ser-61 Asn-157 Thr-159 Asn-167 Thr-169

olaratumabum #
olaratumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* PDGFRA (platelet-derived growth factor receptor alpha subunit, CD140a, PDGFR2)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-457) [*Homo sapiens* VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (236-236'':239-239'')-bisdisulfide dimer

olaratumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* PDGFRA (sous-unité alpha du récepteur du facteur de croissance dérivé des plaquettes, CD140a, PDGFR2)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-457) [*Homo sapiens* VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (236-236'':239-239'')-bisdisulfure

olaratumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* PDGFRA (subunidad alfa del receptor del factor de crecimiento derivado de las plaquetas, CD140a, PDGFR2)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-457) [*Homo sapiens* VH (IGHV4-39*01 (90.90%) -(IGHD)-IGHJ5*01 G119>D) [10.7.19] (1-127) -IGHG1*03 (128-457)], (230-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (236-236":239-239")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QLQLQESGPG LVKPSSETLSL TCTVSGGSIN SSSYYWGWL R QSPGKGLEWI 50
GSFFYTGSTY YNPSLRSLT ISVDTSKNQF SLMLSSVTAA DTAVYYCARQ 100
STYYYGSGNY YGWFDWDQD TLVTVSSAST KGPSVFPLAP SSKSTSGGTA 150
ALGCLVKDYF PEPVTSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVPS 200
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKHTCPCP APELLGGPSV 250
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK 300
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 350
GQPREPQVYT LPFSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 400
YKTTTPVLDL DGSFFLYSKL TVDKSRWQQG NVFSCSVME ALHNHYTQKS 450
LSLSPGK 457

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQK QAPRLLIYD 50
ASNRATGIPA RFSGSGSGTD FTLTISLEP EDFAVYYCQ RSNWPPAFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWQV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-97 154-210 271-331 377-435
22"-97" 154"-210" 271"-331" 377"-435"
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 230-214' 230"-214"
Inter-H-H 236-236" 239-239"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
30, 30", 307, 307"

olokizumabum

olokizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* IL6 (interleukin 6; IL-6)], humanized monoclonal antibody;
gamma4 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -*Homo sapiens* IGHG4*01 hinge S10(228)>P (121-447)], (134-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (226-226":229-229")-bisdisulfide dimer

olokizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens Homo sapiens* IL6 (interleukine 6; IL-6)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-447) [VH humanisé (*Homo sapiens* IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -*Homo sapiens* IGHG4*01 charnière S10(228)>P (121-447)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (226-226":229-229")-bisdisulfure

olokizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens Homo sapiens* IL6 (interleukina 6; IL-6)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-447) [VH humanizado (*Homo sapiens*IGHV3-72*01 (84.00%) -(IGHD)-IGHJ4*01) [8.10.11] (1-120) -*Homo sapiens*IGHG4*01 bisagra S10(228)>P (121-447)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-33*01 (84.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFNFN DYFMNWVRQA PGKGLEWVAQ 50
MRNKNYQYGT YYAESLEGRF TISRDDSKNS LYLMQNSLKT EDTAVYYCAR 100
ESYYGFTSYW GQGTLLTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDPKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPKPKD 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPDSQSEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLD 400
DGSFPLYSLR TVDKSRWQEG NVFSCSVME ALHNHYTQKS LSLSLGK 447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVIT ITCAASQDIF ISLSWYQQKPKAPKLLIYN 50
ANMLADGVPS RFGSGSGTD FTLTISSLQF EDFATYYCLQ HNSAPYTFGQ 100
GKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
LSPPTKSFN RGE 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-98 147-203 261-321 367-425
 22"-98" 147"-203" 261"-321" 367"-425"
 Intra-L 23'-88' 134'-194'
 23'''-88''' 134'''-194'''
 Inter-H-L 134-214' 134"-214"
 Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297"

opicaponium

opicapone


2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine *N*-oxide

opicapone

N-oxyde de 2,5-dichloro-3-[5-(3,4-dihydroxy-5-nitrophényl)-1,2,4-oxadiazol-3-yl]-4,6-diméthylpyridine

opicapona

N-óxido de 2,5-dicloro-3-[5-(3,4-dihidroxi-5-nitrofenil)-1,2,4-oxadiazol-3-il]-4,6-dimetilpiridina

C₁₅H₁₀Cl₂N₄O₆

orantinibum

orantinib


3-(2,4-dimethyl-5-([(3*Z*)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene]methyl)-1*H*-pyrrol-3-yl)propanoic acid

orantinib

acide 3-(2,4-diméthyl-5-([(3*Z*)-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène]méhyl)-1*H*-pyrrol-3-yl)propanoïque

orantinib

ácido 3-(2,4-dimetil-5-([(3*Z*)-2-oxo-1,2-dihidro-3*H*-indol-3-ilideno]metil)-1*H*-pirrol-3-il)propanoico



oxelumabum #
oxelumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFSF4 (Tumor necrosis factor ligand superfamily member 4, OX40 ligand, OX-40L, TAX transcriptionally-activated glycoprotein 1, TXGP1, gp34, CD252], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (229-229":232-232")-bisdisulfide dimer

oxélumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFSF4 (membre 4 de la superfamille des ligands du facteur de nécrose tumorale, ligand de OX40, OX40L, glycoprotéine 1 activée transcriptionnellement par TAX, TXGP1, CD252], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

oxelumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFSF4 (miembro 4 de la superfamilia de ligandos del factor de necrosis tumoral, ligando de OX40, OX40L, glicoproteína 1 activada por transcripción por TAX, TXGP1, CD252], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01 T122>A) [8.8.13] (1-120) -IGHG1*01 K130>del (121-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
EVQLLESGGG LVQPGGSLRL SCAASGFTFN SYAMSWVRQA PGKLEWVSI 50
ISGSGGFTTY ADSVKGRFTI SRDNRSTLY LQMSLRAD TAVYYCAKDR 100
LVAPGTFDYW GQALVTSS ASTKGPSVFP LAPSSKSTSG GTALGCLVK 150
DYFPEPVTVS WNSGALTVSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKHTCP PCPAPPELLGG PSVFLFPPKP 250
KDTLMISRTPEVTCVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
LSDSGSFFLY SKLTVDKSRW QQGNVFCSV MHEALHNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASVGDRVT ITCRASGIS SWLAWYQKP EKAPKSLIYA 50
ASSLQSGVPS RFGSGSGTD FTLTISLQP EDFATYYCQ YNSYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 147-203 264-324 370-428

22"-96" 147"-203" 264"-324" 370"-428"

Intra-L 23"-88" 134"-194"

23"-88" 134"-194"

Inter-H-L 223-214' 223"-214"

Inter-H-H 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

300, 300"

peginesatidum #
peginesatide



pegylated erythropoietin receptor agonist,
 $N^{6,21}, N^{6,21'} - \{[(N^2, N^6 - \text{bis}[\omega\text{-methoxypoly(oxyethylene)]carbonyl})\text{-L-lysyl-}\beta\text{-alanyl})\text{imino}] \text{bis}(\text{methylenecarbonyl})\} \text{bis}[N\text{-acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(naphthalen-1-yl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-L-methylglycyl-L-lysineamide}] (6 \rightarrow 15:6' \rightarrow 15')\text{-bisdisulfide cyclic}$

péginésatide

agoniste du récepteur de l'érythropoïétine, pégylé
 $(6 \rightarrow 15:6' \rightarrow 15')\text{-bisdisulfure cyclique du } N^{6,21}, N^{6,21'} - \{[(N^2, N^6 - \text{bis}[\omega\text{-méthoxypoly(oxyéthylène)]carbonyl})\text{-L-lysyl-}\beta\text{-alanyl})\text{imino}] \text{bis}(\text{méthylénecarbonyl})\} \text{bis}[\text{acétylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolyl-L-isoleucyl-L-thréonyl-3-(naphtalén-1-yl)-L-alanyl-L-valyl-L-cystéinyl-L-glutaminyl-L-prolyl-L-leucyl-L-arginyl-L-méthylglycyl-L-lysineamide}]$

peginesatida

agonista del receptor de la eritropoyetina, pegilado
 $(6 \rightarrow 15:6' \rightarrow 15')\text{-bisdisulfuro cíclico del } N^{6,21}, N^{6,21'} - \{[(N^2, N^6 - \text{bis}[\omega\text{-metoxipoli(oxietileno)]carbonyl})\text{-L-lisil-}\beta\text{-alanil})\text{imino}] \text{bis}(\text{metilenocarbonil})\} \text{bis}\{S^6, S^{15}\text{-ciclo}[N\text{-acetilglicilglicil-L-leucil-L-tirosil-L-alanil-L-cisteinil-L-histidil-L-metionilglicil-L-prolil-L-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-L-valil-L-cisteinil-L-glutaminil-L-prolil-L-leucil-L-arginil-L-metilglicil-L-lisinamida}]\}$



ponesimodum

ponesimod


(2Z,5Z)-5-{3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenylmethylidene}-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-4-one

ponésimod

(2Z,5Z)-5-{3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phénylméthylidène}-3-(2-méthylphényl)-2-(propylimino)-1,3-thiazolidin-4-one

ponesimod

(2Z,5Z)-5-{3-cloro-4-[(2R)-2,3-dihidroxiopropoxi]fenilmetilideno}-3-(2-metilfenil)-2-(propilimino)-1,3-tiazolidin-4-ona

C₂₃H₂₅ClN₂O₄S**rezatomidinum**

rezatomidine


4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydro-2H-imidazol-2-thione

rézatomidine

4-[(1S)-1-(2,3-diméthylphényl)éthyl]-1,3-dihydro-2H-imidazole-2-thione

rezatomidina


4-[(1S)-1-(2,3-dimetilfenil)etil]-1,3-dihidro-2H-imidazol-2-tiona

C₁₃H₁₆N₂S**roledumabum #**

roledumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* RHD (Rhesus blood group D antigen, RhD, CD240D)], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-456) [*Homo sapiens* VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (235-235'':238-238'')-bisdisulfide dimer

rolédumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> RHD (antigène groupe sanguin Rhésus D, RhD, CD240D)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (235-235":238-238")-bisdisulfure
roledumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> RHD (antígeno sanguíneo D Rhesus, RhD, CD240D)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-456) [<i>Homo sapiens</i> VH (IGHV3-30*01 (86.70%) -(IGHD)-IGHJ3*02) [8.8.19] (1-126) -IGHG1*01 (127-456)], (229-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV1-8*01 (89.50%) -IGKJ1*01 K123>R, K127>T) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (235-235":238-238")-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGKSLRL SCTASGFTFK NYAMHWVRQA PAKGLEWVAT 50 ISYDGRNIQY ADSVKGRFTF SRDNSQDTLY LQLNSLRPED TAVYYCARPV 100 RSRWLQLGLE DAFHIWGGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA 150 LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVTVTPSS 200 SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF 250 LFPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300 REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNNKALPAP IEKTISKAKG 350 QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY 400 KTTTPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL 450 SLSFGK 456 Light chain / Chaîne légère / Cadena ligera AIRMTQSPSS FSASTGDRVT ITCRASQDIR NYVAWYQQKS GKAPKFLIYA 50 ASTLQSGVPS RFGSGSGTD FTLTINSLSQ EDFATYYCQQ YYNSPPTFGQ 100 GTRVEITRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWQV 150 DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200 LSSPVTKSFN RGEK 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 153-209 270-330 376-434 22"-96" 153"-209" 270"-330" 376"-434" Intra-L 23'-88' 134'-194' 23"-88" 134"-194" Inter-H-L 229-214' 229"-214" Inter-H-H 235-235" 238-238" N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 306, 306"
ruxolitinibum ruxolitinib	(3 <i>R</i>)-3-cyclopentyl-3-[4-(7 <i>H</i> -pyrrolo[2,3- <i>d</i>]pyrimidin-4-yl)-1 <i>H</i> -pyrazol-1-yl]propanenitrile
ruxolitinib	(3 <i>R</i>)-3-cyclopentyl-3-[4-(7 <i>H</i> -pyrrolo[2,3- <i>d</i>]pyrimidin-4-yl)-1 <i>H</i> -pyrazol-1-yl]propanenitrile
ruxolitinib	(3 <i>R</i>)-3-ciclopentil-3-[4-(7 <i>H</i> -pirrolo[2,3- <i>d</i>]pirimidin-4-il)-1 <i>H</i> -pirazol-1-il]propanonitrilo



samalizumabum #
samalizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* CD200 (OX-2)], humanized monoclonal antibody;
gamma2 heavy chain (1-442) [humanized VH (*Homo sapiens*IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (219-219'':220-220'':223-223'':226-226'')-tetrakisdisulfide dimer

samalizumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-442) [VH humanisé (*Homo sapiens*IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-charnière-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (219-219'':220-220'':223-223'':226-226'')-tétrakisdisulfure

samalizumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticuerpo monoclonal humanizado; cadena pesado gamma2 (1-442) [humanizado VH (*Homo sapiens*IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada(*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (219-219'':220-220'':223-223'':226-226'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
QVQLQQSGSE LKKPGASVKI SCKASGYSFT DYIILWVRQN PGKGLEWIGH 50
IDPYYGSSNY NLKFKGRVTI TADQSTTTAY MELSSSLRSED TAVYYCGRSK 100
RDYFDYWGQG TLTIVSSAST KGPSVFFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPV SNFGTQTYTC 200
NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTKRSLSLG LG 442

Light chain / Chaîne légère / Cadena ligera
DIQMTQSPSS LSASIGDRVIT TCKASQDIN SYLSWFQKPK GKAPKLLIYR 50
ANRLVDGVPS RFGSGSGSDT YTLTISSLQP EDFAVYYCLQ YDEFPYTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGECH 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22"-96" 144"-200" 257"-317" 363"-421"
22"-96" 144"-200" 257"-317" 363"-421"
Intra-L 23'-88' 134'-194'
23"-88" 134"-194"
Inter-H-L 131"-214" 131"-214"
Inter-H-H 219"-219" 220"-220" 223"-223" 226"-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
293, 293"

simenepagum
simenepag

5-(((2*R*)-1-{4-[(1*S*)-1-hydroxyhexyl]phenyl}-5-oxopyrrolidin-2-yl)methoxy)methylthiophene-2-carboxylic acid


siménépag

acide 5-(((2*R*)-1-{4-[(1*S*)-1-hydroxyhexyl]phényl}-5-oxopyrrolidin-2-yl)méthoxy)méthylthiophène-2-carboxylique

simenepag

ácido 5-(((2*R*)-1-{4-[(1*S*)-1-hidroxihexil]fenil}-5-oxopirrolidin-2-il)metoxi)metiltiofeno-2- carboxílico

C₂₃H₂₉NO₅S



somatropinum pegolum #
somatropin pegol

N^{5,141}-[(2*E*)-({2-[(2,3-bis[ω-methoxypoly(oxyethylene)]propoxy)=carbonyl}amino)ethoxyimino)ethyl]human somatotropin (growth hormone)

somatropine pégol

N^{5,141}-[(2*E*)-({2-[(2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy)=carbonyl}amino)éthoxyimino)éthyl]somatotropine humaine (hormone de croissance)


somatropina pegol

N^{5,141}-[(2*E*)-({2-[(2,3-bis[ω-metoxipoli(oxietileno)]propoxi)carbonil]=amino)etoxi}imino)etil]somatotropina humana (hormona de crecimiento)

FPTIPLSRLF DNAMLRHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT 50
 SLCFSES IPT PSNREETQOK SNLELLRISL LLIQSWLEPV QFLRSVFANS 100
 LVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFK QTYSKFDNTS 150
 HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F 191

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 53-165 182-189

Modified residue / Résidu modifié / Residuo modificado



taprenepagum
 taprenepag

2-{3-[(N-{[4-(1*H*-pyrazol-1-yl)phenyl]methyl}pyridine-3-sulfonamido)methyl]phenoxy}acetic acid


taprénépag

acide 2-{3-[(N-{[4-(1*H*-pyrazol-1-yl)phényl]méthyl}pyridine-3-sulfonamido)méthyl]phénoxy}acétique

taprenepag

ácido 2-{3-[(N-{[4-(1*H*-pirazol-1-il)fenil]metil}piridina-3-sulfonamido)metil]fenoxi}acético

C₂₄H₂₂N₄O₅S



tedalinabum
 tedalinab

(4*S*,7*R*)-*N*-*tert*-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-1*H*-4,7-methanoindazole-3-carboxamide


tédalinab

(4*S*,7*R*)-*N*-*tert*-butyl-1-(2,4-difluorophényl)-4,5,6,7-tétrahydro-1*H*-4,7-méthanoindazole-3-carboxamide

tedalinab

(4*S*,7*R*)-*N*-*terc*-butil-1-(2,4-difluorofenil)-4,5,6,7-tetrahidro-1*H*-4,7-metanoindazol-3-carboxamida

C₁₉H₂₁F₂N₃O



tegobuvirum


tegobuvir

5-({6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)-
2-(2-fluorophenyl)-5*H*-imidazo[4,5-*c*]pyridine

tégobuvir

5-({6-[2,4-bis(trifluorométhyl)phényl]pyridazin-3-yl}méthyl)-
2-(2-fluorophényl)-5*H*-imidazo[4,5-*c*]pyridine

tegobuvir

5-({6-[2,4-bis(trifluorometil)fenil]piridazin-3-il}metil)-2-(2-fluorofenil)-
5*H*-imidazo[4,5-*c*]piridina $C_{25}H_{14}F_7N_5$ **telapristonum**


telapristone

11β-[4-(dimethylamino)phenyl]-17-hydroxy-21-methoxy-
19-norpregna-4,9-diene-3,20-dione

télapristone

11β-[4-(diméthylamino)phényl]-17-hydroxy-21-méthoxy-
19-norprégna-4,9-diène-3,20-dione

telapristona

11β-[4-(dimetilamino)fenil]-17-hidroxi-21-metoxi-19-norpregna-
4,9-dieno-3,20-diona $C_{29}H_{37}NO_4$ **temanogrelum**


temanogrel

3-methoxy-*N*-{3-(1-methyl-1*H*-pyrazol-5-yl)-4-[2-(morpholin-
4-yl)ethoxy]phenyl}benzamide

témanogrel

3-méthoxy-*N*-{3-(1-méthyl-1*H*-pyrazol-5-yl)-4-[2-(morpholin-
4-yl)éthoxy]phényl}benzamide

temanogrel

N-{3-(1-metil-1*H*-pirazol-5-il)-4-[2-(morfolin-4-il)etoxi]fenil}-
3-metoxibenzamida $C_{24}H_{28}N_4O_4$ 

tiprelestatum

tiprelestat

human elafin (elastase-specific inhibitor, skin-derived antileukoproteinase, peptidase inhibitor 3)

tiprélestat

élafine humaine (inhibiteur spécifique de l'élastase, antileukoprotéinase dérivé de la peau, inhibiteur 3 de peptidase)

tiprelestat

elafina humana (inhibidor específico de la elastasa, antileukoproteínasa derivada de la piel, inhibidor 3 de peptidasa)

C₂₅₄H₄₁₆N₇₂O₇₅S₁₀

AQEPVKGPVS TKPGSCPIIL IRCAMLNPPN RCLKDTDCPG IKKCCGSGCG 50
 MACFVPQ 57

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 16-45 23-49 32-44 38-53

tivantinibum


tivantinib

(3*R*,4*R*)-3-(5,6-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-1-yl)-4-(1*H*-indol-3-yl)pyrrolidine-2,5-dione

tivantinib

(3*R*,4*R*)-3-(5,6-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinoléin-1-yl)-4-(1*H*-indol-3-yl)pyrrolidine-2,5-dione

tivantinib

(3*R*,4*R*)-3-(5,6-dihidro-4*H*-pirrolo[3,2,1-*ij*]quinolein-1-il)-4-(1*H*-indol-3-il)pirrolidina-2,5-dionaC₂₃H₁₉N₃O₂**tofogliflozinum**

tofogliflozin


(1*S*,3'*R*,4'*S*,5'*S*,6'*R*)-6-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3*H*-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol

tofogliflozine

(1*S*,3'*R*,4'*S*,5'*S*,6'*R*)-6-[(4-éthylphényl)méthyl]-6'-(hydroxyméthyl)-3',4',5',6'-tétrahydro-3*H*-spiro[2-benzofuran-1,2'-pyran]-3',4',5'-triol

tofogliflozina

(1*S*,3'*R*,4'*S*,5'*S*,6'*R*)-6-[(4-etilfenil)metil]-6'-(hidroximetil)-3',4',5',6'-tetrahidro-3*H*-espiro[2-benzofurano-1,2'-pirano]-3',4',5'-triol



trastuzumabum emtansinum #
trastuzumab emtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB2 (epidermal growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)], humanized monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) - *Homo sapiens*IGHG1*03 (121-449) CH1 R120>K], (223-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens*IGKC*01 (108'-214')]; (229-229":232-232")-bisdisulfide dimer; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker
For the *emtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

trastuzumab emtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB2 (récepteur 2 du facteur de croissance épidermique, HER-2, p185c-erbB2, NEU, EGFR2)], anticorps monoclonal humanisé conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) - *Homo sapiens*IGHG1*03 (121-449) CH1 R120>K], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens*IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC)
Pour la partie *emtansine*, veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

trastuzumab emtansina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB2 (receptor 2 del factor de crecimiento epidérmico, HER-2, p185c-erbB2, NEU, EGFR2)]], anticuerpo monoclonal humanizado conjugado con maitansinoide DM1;
cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens*IGHV3-66*01 (81.60%) -(IGHD)-IGHJ6*01 T123>L) [8.8.13] (1-120) - *Homo sapiens*IGHG1*03 (121-449) CH1 R120>K], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens*IGKC*01 (108'-214')]; dimero (229-229'':232-232'')-bisulfuro; conjugado, en 3 a 4 residuos lisil por término medio, con el maitansinoide DM1 mediante un conector succinimidil-4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC)
Por la parte *emtansina*, por favor, vaya al documento "*INN for pharmaceutical substances: Names for radicals, groups & others*".

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR 50
IYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG 100
GDGFYAMDYW GQGTLLTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTYS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHHKPS NTKVDKKVEP KSCDKTHTCP PCPAPPELLGG PSVFLFPPKP 250
KDTLMISRTPEVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
LSDSGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG 449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS 50
ASFLYSGVPS RFGSGRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGECC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L 23'-88" 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 223-214' 223"-214"
Inter-H-H 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

300, 300"

ulimorelinum

ulimorelin



(2*R*,5*S*,8*R*,11*R*)-5-cyclopropyl-11-[(4-fluorophenyl)methyl]-2,7,8-trimethyl-2,3,4,5,7,8,10,11,13,14,15,16-dodecahydro-6*H*-1,4,7,10,13-benzoxatetraazacyclooctadecine-6,9,12-trione

ulimoréline

(2*R*,5*S*,8*R*,11*R*)-5-cyclopropyl-11-[(4-fluorophényl)méthyl]-2,7,8-triméthyl-2,3,4,5,7,8,10,11,13,14,15,16-dodécahydro-6*H*-1,4,7,10,13-benzoxatétrazacyclooctadécine-6,9,12-trione

ulimorelina

(2*R*,5*S*,8*R*,11*R*)-5-ciclopropil-11-[(4-fluorofenil)metil]-2,7,8-trimetil-2,3,4,5,7,8,10,11,13,14,15,16-dodecahidro-6*H*-1,4,7,10,13-benzoxatetraazaciclooctadecino-6,9,12(5*H*)-triona

**umifenovirum**


umifenovir

ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1*H*-indole-3-carboxylate

umifénovir

6-bromo-4-[(diméthylamino)méthyl]-5-hydroxy-1-méthyl-2-[(phénylsulfanyl)méthyl]-1*H*-indole-3-carboxylate d'éthyle

umifenovir

6-bromo-4-[(dimetilamino)metil]-5-hidroxi-1-metil-2-[(fenilsulfanil)metil]-1*H*-indol-3-carboxilato de etilo**umirolimusum**

umirolimus



(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]-1-méthylethyl]-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34^a-octadecahydro-23,27-epoxy-5*H*-pyrido[2,1-*c*][1,4]oxazacyclohentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone

umirolimus

(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-ethoxyethoxy)-3-méthoxycyclohexyl]-1-méthylethyl]-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34^a-octadecahydro-23,27-epoxy-5*H*-pyrido[2,1-*c*][1,4]oxazacyclohentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone

umirolimús



(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-(2-etoxyetoxi)-3-metoxiciclohexil]-1-metiletil]-9,27-dihidroxi-10,21-dimetoxi-6,8,12,14,20,26-hexametil-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34^a-octadecahidro-23,27-epoxi-5*H*-pirido[2,1-*c*][1,4]oxazaciclohentriacontina-1,5,11,28,29(6*H*,31*H*)-pentona

**uridini triacetatas**

uridine triacetate

triacétate d'uridine

triacetato de uridina

2',3',5'-tri-*O*-acetyluridine2',3',5'-tri-*O*-acétyluridine2',3',5'-tri-*O*-acetiluridina**vaniprevirum**

vaniprevir


vaniprévir

vaniprevir

(5*R*,7*S*,10*S*)-10-*tert*-butyl-*N*-{[(1*R*,2*R*)-1-[*N*-(cyclopropanesulfonyl)carbamoyl]-2-ethylcyclopropyl]-15,15-dimethyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahydro-1*H*,3*H*,5*H*-2,23:5,8-dimethano-4,13,2,8,11-benzodioxatriazacyclohenicosine-7-carboxamide

(5*R*,7*S*,10*S*)-10-*tert*-butyl-*N*-{[(1*R*,2*R*)-1-[*N*-(cyclopropanesulfonyl)carbamoyl]-2-éthylcyclopropyl]-15,15-diméthyl-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodécahydro-1*H*,3*H*,5*H*-2,23:5,8-diméthano-4,13,2,8,11-benzodioxatriazacyclohénicosine-7-carboxamide

(5*R*,7*S*,10*S*)-10-*terc*-butil-*N*-{[(1*R*,2*R*)-1-[*N*-(ciclopropanosulfonyl)carbamoi]-2-etilciclopropil}-15,15-dimetil-3,9,12-trioxo-6,7,9,10,11,12,14,15,16,17,18,19-dodecahidro-1*H*,3*H*,5*H*-2,23:5,8-dimetano-4,13,2,8,11-benzodioxatriazaciclohenicosina-7-carboxamida

$C_{38}H_{55}N_5O_9S$ 

vemurafenibum
vemurafenib


N-{3-[5-(4-chlorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide

vémurafénib

N-{3-[5-(4-chlorophényl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-carbonyl]-2,4-difluorophényl}propane-1-sulfonamide

vemurafenib

N-{3-[5-(4-clorofenil)-1*H*-pirrolo[2,3-*b*]piridin-3-carbonil]-2,4-difluorofenil}propano-1-sulfonamida

 $C_{23}H_{18}ClF_2N_3O_3S$ 

verubulinum
verubulin


N-(4-methoxyphenyl)-*N*,2-dimethylquinazolin-4-amine

vérubuline

N-(4-méthoxyphényl)-*N*,2-diméthylquinazolin-4-amine

verubulina

N,2-dimetil-*N*-(4-metoxifenil)quinazolin-4-amina

 $C_{17}H_{17}N_3O$ 

vidofludimusum


vidofludimus

2-[*N*-(3-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl)carbamoyl]cyclopent-1-ene-1-carboxylic acid

vidofludimus

acide 2-[*N*-(3-fluoro-3'-méthoxy[1,1'-biphényl]-4-yl)carbamoyl]cyclopent-1-ène-1-carboxylique

vidofludimús

ácido 2-[*N*-(3-fluoro-3'-metoxi[1,1'-bifenil]-4-il)carbamoil]ciclopent-1-eno-1-carboxílico $C_{20}H_{18}FNO_4$ **vilanterolum**


vilanterol

4-((1*R*)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl)-2-(hydroxymethyl)phenol

vilantérol

4-((1*R*)-2-[(6-{2-[(2,6-dichlorophényl)méthoxy]éthoxy}hexyl)amino]-1-hydroxyéthyl)-2-(hydroxyméthyl)phénol

vilanterol

4-((1*R*)-2-[(6-{2-[(2,6-diclorofenil)metoxi]etoxi}hexil)amino]-1-hidroxietil)-2-(hidroximetil)fenol $C_{24}H_{33}Cl_2NO_5$ **vipadenantum**

vipadenant


3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-5-amine

vipadénant

3-[(4-amino-3-méthylphényl)méthyl]-7-(furan-2-yl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-5-amine

vipadenant

3-[(4-amino-3-metilfenil)metil]-7-(furan-2-il)-3*H*-[1,2,3]triazolo[4,5-*d*]pirimidin-5-amina

$C_{16}H_{15}N_7O$ **vismodegibum**


vismodegib

2-chloro-*N*-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methanesulfonyl)benzamide

vismodégib

2-chloro-*N*-[4-chloro-3-(pyridin-2-yl)phényl]-4-(méthylsulfonyl)benzamide

vismodegib

2-cloro-*N*-[4-cloro-3-(piridin-2-il)fenil]-4-(metanosulfonyl)benzamida $C_{19}H_{14}Cl_2N_2O_3S$ **vorapaxarum**


vorapaxar

ethyl [(1*R*,3*aR*,4*aR*,6*R*,8*aR*,9*S*,9*aS*)-9-[(1*E*)-2-[5-(3-fluorophenyl)pyridine-2-yl]ethen-1-yl]-1-methyl-3-oxododecahydronaphtho[2,3-*c*]furan-6-yl]carbamate

vorapaxar

[(1*R*,3*aR*,4*aR*,6*R*,8*aR*,9*S*,9*aS*)-9-[(1*E*)-2-[5-(3-fluorophényl)pyridin-2-yl]éthén-1-yl]-1-méthyl-3-oxodécacydronaphto[2,3-*c*]furan-6-yl]carbamate d'éthyle

vorapaxar

[(1*R*,3*aR*,4*aR*,6*R*,8*aR*,9*S*,9*aS*)-9-[(1*E*)-2-[5-(3-fluorofenil)piridin-2-il]eten-1-il]-1-metil-3-oxododecahidronafto[2,3-*c*]furan-6-il]carbamato de etilo $C_{29}H_{33}FN_2O_4$ 

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Recommended International Non Proprietary Names (Rec. INN): List 6
(WHO Chronicle, Vol. 20, No. 11, 1966)**

dalanatum insulinum		
p. 424	dalanated insulin	<i>replace the description by the following</i>
		an insulin derivative prepared by the removal of the C-terminal alanine from the B chain of insulin

**Recommended International Non Proprietary Names (Rec. INN): List 31
Denominations communes internationales recommandées (DCI Rec.): Liste 31
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 31
(WHO Drug Information, Vol. 5, No. 3, 1991)**

p. 13	<i>delete/supprimer/suprimáse</i>	<i>insert/insérer/insertese</i>
	suplatastum tosilas	suplatasti tosilas

**Recommended International Non Proprietary Names (Rec. INN): List 51
Denominations communes internationales recommandées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)**

p. 102	<i>delete/supprimer/suprimáse</i>	<i>insert/insérer/insertese</i>
	ralfinamidum	priralfinamidum
	ralfinamide	priralfinamide
	ralfinamide	priralfinamide
	ralfinamida	priralfinamida

**Recommended International Non Proprietary Names (Rec. INN): List 59
Denominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)**

p. 66	<i>delete/supprimer/suprimáse</i>	<i>insert/insérer/insertese</i>
	sergliflozinum etabonas	sergliflozini etabonas

**Recommended International Non Proprietary Names (Rec. INN): List 63
Denominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)**

p. 56	fonturacetamum	
	fonturacetam	<i>replace the chemical name by the following</i>
	fonturacétam	<i>remplacer le nom chimique par le suivant</i>
	fonturacetam	<i>sustitúyase el nombre químico por el siguiente</i>
		<i>rac-2-(2-oxo-4-phenylpyrolidin-1-yl)acetamide</i>
		<i>rac-2-(2-oxo-4-phénylpyrolidin-1-yl)acétamide</i>
		<i>rac-2-(4-fenil-2-oxopirrolidin-1-il)acetamida</i>

p. 74 **sifalimumabum**

sifalimumab
sifalimumab
sifalimumab

replace the description by the following
remplacer la description par la suivante
sustitúyase la descripción por la siguiente

immunoglobulin G1-kappa, anti-[*Homo sapiens* interferon alpha (IFN-alpha)],
Homo sapiens monoclonal antibody;
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV1-18*01 (95.90%) -
(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1 R120>K (213) (117-446)],
(219-213')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA
(IGKV3-20*01 (99.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')];
(225-225'':228-228'')-bisdisulfide dimer

immunoglobuline G1-kappa, anti-[*Homo sapiens* interféron alpha (IFN-alpha)],
Homo sapiens anticorps monoclonal;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV1-18*01 (95.90%) -
(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1 R120>K (213) (117-446)],
(219-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-
KAPPA (IGKV3-20*01 (99.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-
215')]; dimère (225-225'':228-228'')-bisdisulfure

inmunoglobulina G1-kappa, anti-[interferón alfa (IFN-alfa) de *Homo sapiens*],
anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV1-18*01
(95.90%) - (IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG1*03 CH1
R120>K (213) (117-446)], (219-215')-disulfuro con la cadena ligera kappa
(1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -
IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (225-
225'':228-228'')-bisdisulfuro

Recommended International Non Proprietary Names (Rec. INN): List 64**Denominations communes internationales recommandées (DCI Rec.): Liste 64****Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64****(WHO Drug Information, Vol. 24, No. 3, 2010)**p. 260 **afatinibum**

afatinib
afatinib
afatinib

replace the chemical name by the following
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-[[[(3S)-oxolan-3-yl]oxy]quinazolin-6-yl]-4-(dimethylamino)but-2-enamide

(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-[[[(3S)-oxolan-3-yl]oxy]quinazolin-6-yl]-4-(diméthylamino)but-2-énamide

(2E)-N-[4-(3-cloro-4-fluoroanilino)-7-[[[(3S)-oxolan-3-il]oxi]quinazolin-6-il]-4-(dimetilamino)but-2-enamida

p. 279 **sotaterceptum**

sotatercept

replace the description by the following

sotatercept

remplacer la descriptions par la suivante

sotatercept

sustitúyase la descripción por la siguiente

fusion protein for immune applications (FPIA) comprising *Homo sapiens* ACVR2A (activin receptor type 2A, activin receptor type IIA) fragment fused with *Homo sapiens* immunoglobulin G1 Fc fragment; *Homo sapiens* ACVR2A, 21-135 precursor fragment (1-115) -threonyl-triglycyl linker (116-119) -gamma1 chain H-CH2-CH3 fragment (120-344) [*Homo sapiens* IGHG1*03 hinge (120-127), CH2, A115>V (227) (128-237), CH3 (238-344)]; (123-123':126-126')-bisdisulfide dimer

protéine de fusion pour applications immunitaires (FPIA) comprenant un fragment d'*Homo sapiens* ACVR2A (récepteur type 2A de l'activine, récepteur type IIA de l'activine) fusionné au fragment Fc de l'*Homo sapiens* immunoglobuline G1; fragment précurseur 21-135 de *Homo sapiens* ACVR2A (1-115) -linker thréonyl-triglycyl (116-119) -fragment H-CH2-CH3 de chaîne gamma1 (120-344) [*Homo sapiens* IGHG1*03 charnière (120-127), CH2, A115>V (227) (128-237), CH3 (238-344)]; dimère (123-123':126-126')-bisdisulfure

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende un fragmento de ACVR2A (receptor tipo 2A de la activina, receptor tipo IIA de la activina) de *Homo sapiens* fusionado al fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*; fragmento precursor 21-135 de ACVR2A de *Homo sapiens* (1-115)-conector treonil-triglicil (116-119) -fragmento H-CH2-CH3 de cadena gamma1 (120-344) [*Homo sapiens* IGHG1*03 bisagra(120-127), CH2, A115>V (128-237), CH3 (238-344)]; dímero (123-123':126-126')-bisdisulfuro

Electronic structure available on Mednet: <http://mednet.who.int/>

Structure électronique disponible sur Mednet: <http://mednet.who.int/>

Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

* "INN for pharmaceutical substances: Names for radicals, groups & others" document available at / document disponible à / documento disponible en : <http://www.who.int/medicines/services/inn/publication/en/index.html>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.